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INTRODUCTION 
   Rheumatic valvular Heart disease is still epidemic in India. The 
occurrence rate of rheumatic heart disease in developing countries is 
substantial. The continued prevalence of rheumatic heart disease is 
developing counties is not related to limited availability of penicillin but 
to their socioeconomic status. According to the annual report by the 
World Health Federation, an estimated 12 million people are currently 
affected by rheumatic fever and rheumatic heart disease worldwide. 
Several studies conducted on the prevalence of rheumatic heart disease 
reported a prevalence of 34.54/1000 in India. Awareness of rheumatic 
heart disease has also prevailed due to widespread use of transthoracic 
echocardiography. Furthermore, demands for adequate medical therapies 
are expanding with increasing use of Percutaneous transvenous mitral 
valvuloplasty. 
In comparison to the surgical mitral commissurotomy Percutaneous 
mitral valvotomy has shown better success rates, comparable restenosis 
rates, larger valve area and long term durability. 
In the case of moderate to severe MS, one has to assess the 
anatomy of the mitral valve meticulously with regard to the feasibility 
and outcome of  percutaneous mitral valvotomy. The most widely used 
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echocardiographic parameter is the Wilkins score which we follow in our 
institute. 
Mitral valve anotomy assessed by 2-D Echo is a strong predictor of 
the immediate results of  percutaneous mitral valvotomy.The binary 
endpoint of immediate procedural success is a final valve area of 1.5 cm 2 
without moderate or severe mitral regurgitation.  
Therefore our study aims to analyse the immediate hemodynamic 
outcomes in patients selected by specific clinical and echo criteria, by 
assessing mitral valve area and other hemodynamic parameters 
immediate post Percutaneous mitral valvotomy, by combined 
retrospective and prospective observational study in our institute, and 
thus throw a light on the benefits of increasing the outreach of  
percutaneous transvenous mitral valvotomy in decreasing the morbidity  
of the Rheumatic heart disease / Mitral stenosis in our country 
     
  
AIMS AND OBJECTIVES 
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AIMS AND OBJECTIVES: 
 
PRIMARY OBJECTIVE: 
To assess the immediate hemodynamic outcomes of Percutaneous 
transvenous mitral commisurotomy done at our institution in patients 
with rheumatic mitral stenosis selected by specific clinical and 
echocardiographic morphological Criteria 
 
SECONDARY OBJECTIVES:  
1. To study clinical outcomes and complications during the procedure 
2. To assess the effectiveness of Wilkins echo score in patient selection 
for   PTMC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
 
 Rheumatic heart disease is a major cause of morbidity and 
mortality among both developed countries and developing countries. The 
incidence is still high in developing countries due to poor socioeconomic 
and environmental conditions. Most of the patients with rheumatic heart 
disease have mitral stenosis, accounting to 40% of isolated mitral stenosis 
and remaining 35% of patients having mitral stenosis with aortic value 
disease together. Most common cause of mitral stenosis is also rheumatic 
etiology. Patients having isolated mitral stenosis give a positive history of 
rheumatic fever in around 50% of the cases. Incidence of rheumatic 
mitral stenosis has female preponderance, the reasons are largely 
unknown. The ratio of female to male incidence 2 : 1. In our institution 
among the patients selected for the percutaneous transvenous mitral 
commissurotomy, the 78% were female, 22% were female. 
Overcrowding, poor sanitation and environmental pollution are 
responsible for the high incidence in developing countries. This is 
because of the higher incidence of group A β hemolytic streptococci in 
these conditions. Incidence of acute rheumatic fever is higher in children 
of school going age around 100% of patients developing rheumatic fever 
will develop rheumatic heart disease. 
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Brunton was the first person who introduced the concept of mitral 
valvotomy in 1902. Then Eliot cutler was the first to perform a closed 
mitral commissurotomy in the year 1923. Harshen and Bailey performed 
many commissurotomies and improvised the procedure. In 1960, open 
commissurotomy was started. In 1976, a Japanese surgeon called kanji 
Inou proposed a new technique using a balloon catheter. Severe trails 
followed using this balloon technique and first successful percutaneous 
transvenous mitral commissurotomy was done in the year 1980. In 1986, 
the double balloon technique was used. Since then many modifications 
have been done in the balloon technique and now percutaneous 
transvenous mitral commissurotomy has become the procedure of choice 
for treating patients with severe mitral stenosis who are carefully selected 
by specific clinical and echocardiography. 
 
GROSS PATHOLOGY OF MITRAL STENOSIS: 
 Rheumatic inflammatory changes affect the four parts of mitral 
value as follows – commissures, cusps, chordae and combined. Out of 
these commissures are severely affected. This inflammation results in the 
mitral value becoming a funnel shaped structure. The mitral value 
opening assumes a button hole or fish mouth structures. Rheumatic 
inflammation can be followed by speck of calcification. Leaflet 
calcification and commissural calcification are common. Calcification 
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can be nodular or plaque type calcification. The chordae tendinae may get 
shortened or fused. The presence of these changes affecting the 
subvalvular apparatus makes a candidate less sensitive for percutaneous 
transvenous mitral commissurotomy. Due to the tight mitral stenosis and 
high gradient across the mitral value, the left atrium is enlarged with 
enlargement of the left atrial appendage and thrombus formation. The 
progressive enlargement of left atrium also leads to increased incidence 
of atrial fibrillation, with increased severity of the stenosis. The atrial 
surface of the mitral valve may show vegetations, the chordate tendinae 
become thickened, firm and shortened and get adhered to each other. Left 
ventricular dimensions are reduced and in severe cases may be atrophic. 
The root of the pulmonary artery can also become dilated. Due to 
pulmonary hypertension right ventricle also becomes dilated and the 
pressure of ball value thrombus in the right atrium will increase the 
degree of stenosis. Thrombus may be confined to the appendage alone or 
can be extending freely into the atrial cavity. In some case left atrial free 
wall can also be calcified. The hallmark finding of rheumatic mitral 
stenosis is commissural fusion. Chordal shortening can be severe enough 
so that the tip of the valve leaflet seems attached directly to the papillary 
muscles. 
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 Papillary muscles can be fibrosed and atrophic. Lambl’s 
excrescences can be seen which are present over the atrial surface. 
Vegetations of acute rheumatic fever are seen along the leaflet margins. 
 In mitral valve which was previously treated with 
commissurotomy, healed fracture lines can be seen. Restenosis can occur 
in these valves which can be due to a recurrent episode of rheumatic fever 
or previous inadequate surgery. When patients develop pulmonary 
hypertension there is medial hypertrophy of median sized pulmonary 
arteries. 
 
PATHOPHYSIOLOGY AND HAEMODYNAMICS: 
 Due to the stenosed valve, the pressure gradient across the mitral 
valve increases during diastole. The left atrial pressure is normally less 
than 5mmHg. Left ventricular diastolic is around 5mmHg. In mitral 
stenosis, the left atrial pressure rises more than 25mmHg. When left atrial 
pressure raises more than 25mmHg, pulmonary edema develops. The 
amount of blood flow across the mitral valve also reduced leading to a 
decreased cardiac output. 
 
SEVERITY OF MITRAL STENOSIS: 
 In mitral stenosis the mean gradient across the mitral valve, 
pulmonary artery systolic pressure and the valve area are the three 
parameters used to assess the severity of mitral stenosis. Mean gradient of 
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less than 5 is mild, 5-10 is moderate, >10 is severe. Pulmonary artery 
systolic pressure <30 is considered as mild, 30-50 mmHg is considered as 
moderate, >50 mmHg is severe. Mitral valve orifice area of >1.5 cm2 is 
mild, 1-1.5 cm2 is moderate, <1.0 cm2 is severe. 
 
 Mitral valve pressure gradient depends on two parameters. These 
are mitral valve area and the mitral valve flow rate. Flow rate increases in 
condition producing tachycardia like exercise, pregnancy, 
hyperthyroidism, infections. This results in increased Trans mitral valve 
gradient quadruples with increase in flow rate. Tachycardia also results in 
decreased diastolic filling; the development of atrial fibrillation can also 
result in onset of symptoms. The transmitral gradient is highest in the 
early part of diastole. Decreased diastolic filling time also increase the 
mean left atrial pressure. Narrowing of the mitral valve and extension of 
pulmonary vascular disease, both result in decreased cardiac output. 
Intially exercise cardiac output is decreased. Later resting cardiac output 
is also reduced. 
 
 Onset of atrial fibrillation with loss of atrial contraction leads to 
further deterioration. This is because, atrial fibrillation leads to 
tachycardia and decreased diastolic filling time. Severity of mitral 
stenosis, increasing age, dimensions of left atrium, left atrial pressure all 
determine the onset of atrial fibrillation. Once the patient develops atrial 
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fibrillation, cardiac output falls by 20%. Left ventricular pressures are 
usually normal in mitral stenosis. But left ventricular remodeling can 
occur due to under filling and right ventricular hypertrophy and septal 
hypertrophy.  
 
DIAGNOSIS OF MITRAL STENOSIS: 
 Echocardiography is the main investigation to confirm the disease, 
assessing the degree of involvement of mitral valve and other valves, 
presence of mitral regurgitation, presence of calcifications or subvalvular 
disease, assessing severity of mitral stenosis. So it is the gold standard for 
selecting patients for balloon mitral valvotomy. The parameters in 
Wilkinson score like valve mobility, leaflet thickening, calcification and 
subvalvular diseases are assessed by 2D-ECHO. In mitral stenosis the 
classical findings are thickening of leaflet, fusion of commisures, 
decreased valve mobility. Severity of mitral stenosis is assessed by 2D-
ECHO planimetry by measurement of mitral valve orifice area. 
Parasternal short axis view is used to measure mitral valve orifice area. 
The normal mitral valve orifice area is 4-6 cm2. 
 
 Patients with mitral valve orifice area <1.0 cm2 are considered as 
severe mitral stenosis. Above 1.5 cm2 hemodynamics are not significantly 
affected at rest. 2D-ECHO planimetry is also the most easy and specific 
method for measuring improvement in mitral valve orifice area post 
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percutaneous transvenous mitral commissurotomy. One disadvantage of 
percutaneous transvenous mitral commissurotomy is that it cannot 
reliably measure mitral valve area if the valve is heavily calcified and 
irregular. Planimetry can also be useful in intraoperative period to assess 
the immediate result of the percutaneous transvenous mitral 
commissurotomy procedures by hand held ECHO probe. 
 
 Parasternal short axis view has other uses like finding the degree of 
subvalvular disease. Rheumatic mitral stenosis always has some degrre of 
subvalvular disease. Subvalvular pathology means chordal thickening, 
papillary muscle displacement, chordal fusion, chordal rupture etc. So the 
feasibility of percutaneous transvenous mitral commissurotomy is 
dependent on the degree of subvalvular disease. So wilkins score takes 
into account subvalvular disease as one of the parameter. Patients older 
than 60 years and those with atrial fibrillation may have variability in 
mitral value orifice area measured by 2D planimetry, 3D-ECHO or 
pressure halftime method are preferred in these patients. 
 
 Mean and peak mitral valve gradients (MVMG / MVPG) can also 
be measured by 2D-ECHO. MVPG is not a reliable indicator for 
assessing severity of mitral stenosis. 
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ASSESING SUITABLITY OF MITRAL VALVE MORPHOLOGY 
FOR PTMC: 
 
 It is done by 2D-echocardiography. Leaflet thickening is considered 
as significant if it is >5mm.Leaflet mobility is also assessed in long axis 
parasternal view. Intraoperative fluoroscopy can show the degree of 
valvular calcification. Subvalvular disease is assessed by long axis, short 
axis and apical view. Many ECHO scoring systems are available which are 
used in patient selection for feasibility of percutaneous transvenous mitral 
commissurotomy. The most commonly used one is wilkins ECHO score, 
which we use in our institution. The total score is 16. Minimum are score is 
4. Four parameters which are considered in wilkins score are leaflet 
mobility, leaflet thickening, leaflet calcification and subvalvular disease. 
Each parameter is given a score of 1 to 4. 
 
 In valve mobility, a highly mobile valve with restriction of leaflet tip 
is given a score of 1, mid and back having normal mobility is given a score 
of 2. Only back and is mobile is given a score of 3and when there is no 
mobility given a score of 4. 
 
 In leaflet thickening, normal thickness of leaflet is given a score of 1, 
only margins are thickened is given a score of 2. When whole leaflet is 
thickened (<8 mm) the score is 3 and thickening of more than 8mm is 
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given a score of 4. With regard to calcification, only a single speck of 
calcification, seen as increased echo brightness is given a score of 1. 
Scattered speck of calcification which is seen along the margins of the 
mitral leaflet is given a score of 2. ECHO brightness extending up to mid 
portion of the valve is given a score of 3. Extensive brightness throughout 
the valve is given a score of 4. 
 
 Subvalvular disease is scored as follows: Minimal thickness below 
the mitral leaflet is scored as 1. The chordate thickening upto one third of 
the length is 2. Thickening of the distal one third is 3. Extensive thickening 
and shortening of chordate extending upto the papillary muscle is 4. Other 
score used is cormier score. But none of the scores are found superior over 
another since large prospective studies are lacking. 
 
EFFECT OF ATRIAL FIBRILLATION: 
Onset of atrial fibrillation with loss of atrial contraction leads to 
further deterioration; this is because atrial fibrillation leads to tachycardia 
and decreased diastolic filling time. Severity of mitral stenosis, increasing 
age, dimensions of left atrium, left atrial pressures all determine the onset 
of atrial fibrillation. Once the patient develops atrial fibrillation, cardiac 
output falls by 20%. Left ventricular pressures are usually normal in mitral 
stenosis. But left ventricular remodeling can occur due to under filling and 
right ventricular hypertrophy and septal hypertrophy.  
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ROLE OF ECHOCARDIOGRAPHY IN PATIENTS WITH 
MITRAL STENOSIS UNDERGOING PERCUTANEOUS MITRAL 
VALVOTOMY 
 
            Echo is the primary modality of patient selection for percutaneous 
mitral commisurotomy . It is also essential component of intra procedural 
monitoring and post procedural assessment and follow up. The absolute 
contraindications for percutaneous mitral commisurotomy are 
commissural calcium, left atrial thrombus and more than 3+ mitral 
regurgitation.The primary aim of ECHO is to assess the suitability of the 
mitral valve for the procedure. The severity of mitral stenosis is primarily 
determined by the mitral valve orifice area.  
 
          Parameters assessed by echocardiography pre-procedure are 
1. Severity of Mitral stenosis 
2. Pliability or suitability of the valve for PTMC  
3. Calcification of the valve 
4. Valve thickening 
5. Sub valvular pathology 
6. Commissural morphology 
7. Mitral regurgitation 
8. Assessment for presence of left atrial thrombus 
9. Diseases of the other valves 
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10. Assessment of intertribal septum 
11. Assessment of pulmonary hypertension 
Intra operatively ECHO is used to assess the adequacy of 
commissural splitting, mitral regurgitation and complications like cardiac 
tamponade. Post operatively ECHO is used to evaluate the adequacy of 
commissural splitting, residual mitral stenosis, mitral regurgitation and 
atrial septal defect 
 
TWO DIMENSIONAL ECHOCARDIOGRAPHY:  
The most important and useful echocardiograph if modality in the 
assessment of suitability of the valve is 2D ECHO. Because valve 
morphology is the most important predictor of the success of 
Percutaneous transvenous mitral valvotomy. In Rheumatic heart disease, 
the mitral valve becomes thickened and mobility of the leaflets becomes 
restricted. This is seen well on the parasternal long axis view or the 
PLAX view. The anterior mitral leaflet shows a hockey stick appearance 
due to coming. The other structures assessed by the 2D ECHO method 
are the aortic and tricuspid valves. Aortic valve is assessed by the PLAX 
and PSAX views and tricuspid valve is assessed by the apical four 
chamber view (A4C) 
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ASSESSMENT OF MITRAL VALVE ORIFICE AREA BY 
PLANIMETRY: 
The planimetry method gives the most accurate valve area and has 
best correlation with MVOA measured autopsy. This is considered as the 
reference method. But it has some limitations because the orthogonality 
of the imaging plane is assumed and not actual. The level at which the 
plane intersects the funnel shaped mitral valve cannot be assessed by the 
measuring person. Presence of commisural calcium makes the 
measurements difficult.  
 
ASSESSMENT OF MITRAL VALVE MORPHOLOGY 
              The primary mechanism by which PTMC brings its 
hemodynamic effects is by splitting of the fused mitral commissures.  
Commissural morphology is the most important determinant factor for 
outcome of PTMC. Valve morphology is assessed by mobility of the 
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valve, thickening of leaflets, subvalvular pathology and calcification. 
Mobility of the valve is assessed by parasternal long axis view or PLAX. 
Wilkins score grades the mobility from 1-4. The extent of coming 
of the mitral valve is assessed. The normal thickness of the mitral valve is 
less than 4 mm. The thickness of 5-8 mm is considered as mild thickening 
and more than 8 mm is severe thickening. Thickening can involve the 
entire leaflet or involves only the margins. Valve thickening is assessed 
on 2D ECHO by PLAX view. 
               More than the valvular calcium the calcium in the commissures 
mostly influences the outcome of PTMC. Commissural calcium is 
assessed by parasternal short axis view. The echogenecity of aortic root is 
used as the reference point. Calcium restricted to the belly of the valve is 
not an absolute contraindication for the procedure. Fibrotic valves usually 
yield less to balloon dilatation.  
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ASSESSMENT OF SUBVALVULAR PATHOLOGY 
Subvalvular pathology is found be an important predictor of 
outcome of PTMC, Because the subvalvular region acts as a secondary 
orifice for the mitral valve. It requires multiple modified views for 
assessment. Subvalvular apparatus is an integral part of the mitral 
structural complex. It includes left ventricle free wall, two papillary 
muscles and chordae tendinae. Both immediate and long term results of 
PTMC are adversely affected by severe subvalvular deformities. 
Therefore proper assessment of patients with rheumatic mitral stenosis 
for the presence of subvalvular disease is important in therapeutic 
decision making, surgical vs palliative.  
 
Both M mode and two dimensional echocardiography are the two 
non invasive methods for evaluating subvalvular disease. Scanning in 
multiple views allows a qualitative assessment of mitral valve apparatus 
like chordal thickening, fusion and calcification. Two dimensional 
echocardiography has limitations in measuring the chordal length, 
differentiating the chordae subgroups and finding the point of insertion.  
 
Wilkins score gives a semi quantitative assessment of subvalvular 
apparatus. Lung and Cormier score gives a more quantitative assessment 
of subvalvular disease. Because it takes into account the chordal length. 
According to this classification, a pliable, non calcified mitral leaflet with 
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thin chordae of more than ten millimetre long have the best chances of 
achieving optimal immediate and long term results after PTMC. 
 
Transesophageal echocardiography has been evaluated over 
transthoracic echocardiography for assessment of subvalvular disease. 
But the results are controversial. In a study by Haussmann et al, 
thickening of subvalvular apparatus was graded lower by monoplane 
transesophageal echocardiography than trans thoracic echocardiography 
due to acoustic shadowing. But transesophageal Echo has no clear 
advantage. Multiplane transesophageal echocardiography was evaluated 
by Stewart et al, and is currently the imaging method of choice for 
evaluation of subvalvular disease. In last decade three dimensional 
echocardiography has been evolving as a means of assessing subvalvular 
disease. 
During PTMC two indirect signs indicate the presence of 
significant subvalvular disease. One is called the balloon impasse sign. 
This indicates crossing and propagation difficulties of the deflated 
balloon catheter into the left ventricle apex due to high resistance at the 
sub mitral region. The balloon compression sign is distortion of inflated 
balloon configuration at the subvalvular level. The normal hour glass 
configuration of the balloon is lost.  
 LEFT ATRIUM, LEFT VENTRICLE, LEFT ATRIAL 
APPENDAGE AND INTERATRIAL SEPTUM
ASSESSMENT FOR PTMC
            Structures other than mitral valve that needs to be assessed are left 
atrium, left atrial appendage and inter atrial septum. Left atr
dilated in mitral stenosis and the si
proportional to the severity of mitral stenosis, duration of obstruction and 
associated mitral regurgitation if any. Sometimes the left atrium can be 
much enlarged and it is called 
evaluated for the presence of thrombus. It is best seen in transesophageal 
echocardiography. In 
ventricle is usually normal in size because there is a constant under
of the LV, but if LV is dilated 
regurgitation or coronary artery diseas
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   Interatrial septum should be carefully assessed to aid in the planning of 
technique of septal puncture. In severe MS, due to dilatation of the left 
atrial chamber, they inter atrial septum bulges into the right atrium. This 
makes the septal puncture difficult. The orientation of the IAS is also 
altered. Some patients who are chosen for re- PTMC can have a residual 
ASD from the previous procedure. Combination of a congenital ASD and 
mitral stenosis is called the lutembacher syndrome.  
           Assessment of other valves is critical because it alters the decision 
regarding choice of surgery. If a patient has a significant aortic valve 
disease he can undergo a simultaneous percutaneous aortic valvotomy 
and if significant tricuspid valve disease is present he can undergo 
simultaneous percutaneous tricuspid valvotomy. 
 
TRANSESOPHAGEAL ECHOCARDIOGRAPHY IN PATIENTS 
UNDERGOING PTMC  
            Transesophageal echocardiography is an integral part of the 
evaluation of patients prior to mitral valvotomy. This is done to rule out 
left atrial thrombus, left atrial appendage thrombus, assessment of mitral 
regurgitation, associated lesions like aortic regurgitation, assessment of 
inter atrial septum to aid in septal puncture. The resolution of trans 
thoracic echocardiography to image the left atrial appendage and the left 
atrium is poor. So it is mandatory to perform a transesophageal 
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echocardiography prior to PTMC, but if TTE shows thrombus 
transesophageal echocardiography can be avoided. The grade of mitral 
regurgitation can be very well assessed by the transesophageal 
echocardiography.  
 
DOPPLER ECHOCARDIOGRAPHY  
             Doppler echocardiography of the mitral valve is important to 
assess the severity of mitral stenosis, the response to balloon dilatation 
and to assess severity of mitral regurgitation. Doppler echocardiography 
of mitral valve is done by apical four chamber view. Mean and peak 
mitral gradient which are important parameters in assessment of outcome 
of surgery are also assessed by the Doppler echocardiography. But these 
gradients are influenced by the heart rate, mitral regurgitation and cardiac 
output.   
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PRESSURE HALFTIME METHOD  
           It is also one of the methods of assessment of mitral valve orifice 
area. This is done by Doppler echocardiography. This method has 
advantages like mitral valve orifice area is less dependent on heart rate, 
less dependent of flow across the mitral valve. It is more accurate in 
patients with atrial fibrillation. It is more accurate in patients with 
residual ASD. 
 
ASSESSMENT OF PULMONARY HYPERTENSION:  
          Presence of pulmonary hypertension determines one of the 
indications for PTMC. Its evaluation in very important in management. 
Pulmonary hypertension is evaluated by echocardiography by indirect 
method. The tricuspid regurgitation jet velocity is measured and the 
estimated right atrial pressure and RV RA pressure gradient is added.  
 
INTRAOPERATIVE ECHOCARDIOGRAPHY: 
             During PTMC Intraoperative echocardiography is performed. 
Trans thoracic echocardiography is most commonly used for this purpose 
because transesophageal echocardiography requires intubation.Trans 
thoracic echocardiography is used to directly visualise the commissural 
splitting with each balloon dilatation and facilitates a graded dilatation. 
Pressure tracing varies according to the heart rate and filling pressure. 
Intraoperative echocardiography is better than assessing LA pressure. 
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Intraoperative echocardiography also gives an idea of the degree of mitral 
regurgitation and increase in the grade of mitral regurgitation by two or 
development of moderate to severe mitral regurgitation is an indication to 
stop the procedure. Intraoperative complications like pericardial effusion 
and tamponade are also assessed. Transseptal puncture is also facilitated 
by echocardiography in addition to the fluoroscopy.  
 
SUCCESSFUL PTMC 
             A successful PTMC results in splitting of one or more of the two 
mitral commissures resulting in increase in MVOA by 50% from baseline 
or final valve area of more than 1.5 cm2 . And there should be a fall in left 
atrial pressure by 50% from baseline. Mean and peak mitral valve 
gradients should fall 50% from baseline. Post PTMC mitral regurgitation 
should not be more than grade two (sellers grade).  
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ECHOCARDIOGRAPHY IN POST OPERATIVE PERIOD 
              Planimetry is used to measure the improvement in MVOA. The 
iatrogenic ASD created for the procedure does not affect the 
measurements done by two dimensional echocardiography. Shunting 
through the iatrogenic ASD is also not hemodynamically significant. 
Commissural Mitral regurgitation usually reduces on follow up 
echocardiography. But mitral regurgitation due to tear of the leaflet or 
damage to the chordal structure needs surgery.  
 
PREDICTIVE VALUE OF VARIOUS ECHOCARDIOGRAPHIC 
PARAMETERS OF MITRAL VALVE MORPHOLOGY BEFORE 
PTMC  
            Outcome of PTMC is influenced by the valve morphology, 
severity of the lesion, the presence of associated lesions, chamber 
anatomy. Mitral valve anatomy is not the only predictor of immediate 
hemodynamic effects of PTMC. Other factors like old age, previous 
valvotomy, higher NYHA class, and presence of atrial fibrillation, female 
gender, small initial MVOA and higher degree of preoperative mitral 
regurgitation, larger size of the left atrium all have effects on the outcome 
of the procedure. The four major echocardiography variables assessed are 
A. Morphology of the mitral valve  
B. Pre-procedural mitral regurgitation  
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C. Mitral valve area prior to PTMC  
D. Left atrial size  
 
MORPHOLOGY OF THE MITRAL VALVE BY VARIOUS 
SCORING SYSTEMS 
           Various multi variate scoring systems have been developed to 
assess the suitability of the valve for PTMC. In 1988, Wilkins scoring 
system was developed by the team in Massachusetts general hospital in 
USA by Wilkins and coworkers. It uses four parameters mitral valve 
calcification, thickening, mobility, and subvalvular fibrosis. Each 
parameter is given a score of one to four. total score is then calculated. 
All patients with a score of less than 9 had optimal results and those with 
score of more than 11 had suboptimal results.  
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             Reid scoring system was developed in 1989 by university of 
South California in the United States. This scoring system also used four 
parameters. Leaflet mobility, thickness, subvalvular disease and 
commissural calcium. Each parameter was given a score of zero to two.  
              Lung and Cormier score was developed by French 
interventionists. It divides patients into three groups, based on pliability, 
calcification and subvalvular disease. This scoring system is unique in 
that it takes chordal length as a parameter. It is also simple to use.   
              Another scoring system is used to predict the possibility of 
developing mitral regurgitation after PTMC. It is called Padial LR mitral 
regurgitation echocardiography scoring. Three factors in anatomy of the 
mitral valve are important in determining whether the patients are prone 
to develop mitral regurgitation. They are uneven mitral valve thickening, 
extensive subvalvular disease and commissural calcium. This scoring 
predicts the development of Mitral regurgitation with a high sensitivity 
and specificity.  
            Ain shams grading system was developed in Egypt in 2008, as a 
novel scoring system. It takes only two parameters into account, 
Calcification and subvalvular involvement. This scoring system has a cut 
off point of four. It successfully predicted poor outcome with high 
sensitivity and specificity  
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        Three dimensional echocardiography scoring system was developed 
by Al- Azhar university in Egypt. It uses real time three dimensional 
echocardiography score for assessment of mitral valve morphology. The 
score ranges from 0 to 31 . Mild disease is less than 8, moderate disease 
is 8- 13, severe disease is more than 13. The major problem with this 
scoring system is its complexity.  
 
DRAWBACKS OF THE SCORING SYSTEMS  
              Grading of the various anatomical features is very subjective and 
therefore not reliable between multiple users. Subvalvular is frequently 
underestimated by both transesophageal and trans thoracic 
echocardiography. However more recent studies still hold that 
echocardiography scores can be independent predictors of outcome. 
Stefenadis et al found that high echocardiography score, male gender, 
pre- procedural mitral regurgitation and previous valvotomy were 
significant unfavourable predictors of outcome. They found that balloon 
type was also a significant multi variate predictor of outcome. This study 
also showed that patients with Wilkins score of less than eight, had a 
greater final MVOA, lower incidence of mitral regurgitation.  
         Many studies have found that Wilkins score can even predict late 
outcome, restenosis and event free survival. So echocardiography 
assessment of mitral valve is still widely used to guide selection of 
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patients. Wilkins score still remains the most widely used score before 
PTMC. Limitations of the Wilkins score are does not assess commissural 
involvement, does not account for Uneven distribution of abnormalities, 
does not give weightage for each variable. Subvalvular disease is 
frequently under estimated, does not use three dimensional 
echocardiography or transesophageal echocardiography.  
 
EFFECT OF PRE-PROCEDURE MITRAL REGURGITATION, 
MVOA, LEFT ATRIAL SIZE 
            Zhang et all found that patients with pre existing mitral 
regurgitation have relatively small improvement in MVOA after PTMC 
and high incidence of late complications. They also had lower possibility 
of bi commissural splitting. This is because these patients have a more 
calcified mitral valve., high incidence of atrial fibrillation, large left 
atrium.  
           Patients with a small MVOA prior to the procedure are expected to 
have a severe valvular and subvalvular pathology. So patients with 
MVOA in the range of 0.4-1 cm2 have a poorer outcome. 
           Left atrial size is also a significant predictor of outcome in most 
reports. Alfonso et al found that patients with aneurysmal dilatation of 
left atrium (>6 cm) had the following characters- they were old, more 
symptomatic, more prone for atrial fibrillation, very severe valve 
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thickening and subvalvular valvular disease, had large left ventricle and 
associated mitral regurgitation, more difficulty in doing trans septal 
puncture, high rate of dilatation failure  
       Other less proven factors affecting the outcome of PTMC are mitral 
annulus diameter and the presence of significant tricuspid regurgitation 
  
OTHER VARIABLES WHICH CAN BE ASSESSED TO FIND 
OUTCOME OF PTMC 
            Not all patients without adequate commissural splitting had 
optimal MVOA. So there may be other factors in mitral valve 
morphology that may have an adjuvant value in assessment of outcome of 
PTMC. These are valve mobility, subvalvular splitting, degree of 
commissural splitting. These parameters are again assessed by the two 
dimensional echocardiography. 
PROCEDURE OF PTMC  
             PTMC is usually done as an inpatient procedure because there is 
always a possibility of complications needing mitral valve replacement, 
so surgical team should be ready in standby. Inoue balloon technique is 
the most common technique used in our hospital.  
             The patient is prepared by Sctimst protocol. Vascular access is 
obtained by right femoral vein. Right femoral artery is used to introduce a 
pigtail catheter to locate aorta.  
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The steps of the procedure are as follows  
1. Obtaining vascular access  
2. Preparation of the septal puncture system and the balloon  
3. Assessing hemodynamics with multipurpose catheter( right atrial 
pressure, pulmonary artery pressure  
4. Septal puncture – technique is described below  
5. Entering the left atrium and balloon inflation 
6. Recording of the pressures in left atrium- after trans septal 
puncture the mullein sheath is in the left atrium through which we 
can record the pressure  
7. Introducing pigtail shaped left atrial guide wire- the pigtail guide 
wire forms a nice loop in the left atrium which is freely movable, 
after placing the loop mullein sheath is withdrawn  
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8. Dilatation of groin access site and inter atrial septum- a fourteen 
French dilator is used. Once the septal dilatation is performed 
Intraoperative echocardiography is done to rule out any pericardial 
effusion. If there is no effusion then heparin is administered. 
 
9. Introduction of the balloon into the left atrium  
 
10. Crossing of the mitral valve and balloon dilatation – done in the 
right anterior oblique view, entry of left ventricle is done, once the 
balloon reaches left ventricular apex it is inflated partly. Partly 
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inflated balloon is pulled back so that the waist of the balloon is 
aligned at the mitral valve orifice. Then the balloon is inflated 
fully.  
11. Assessment after balloon dilatation – left atrial pressure is checked 
after each dilatation  
 
12. Serial dilatation  
13. Assessment of success of the procedure – the success of the 
procedure is assessed by echocardiography showing splitting of 
one or more commissures, decreasing grading in Doppler 
echocardiography, checking the fall in the left atrial pressure.  
14. Assessment of mitral regurgitation  
15. Removing the balloon from the left atrium  
16. Removal of the left atrial guide wire  
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PTMC PROCEDURE- TRANS SEPTAL PUNCTURE  
          Trans septal puncture is the essential step in performing PTMC 
through anterograde route. The Trans septal puncture technique was 
developed by Ross, braunwald and morrow at national institute of health 
to allow left heart catheterisation. The procedure is visualised by 
fluoroscopy by left anterior oblique ( LAO) or right anterior oblique ( 
RAO) view. 
Instruments needed for trans septal puncture are  
1. mullein sheath and dilator  
2. Brockenbrough needle  
3. Three way stop cock with saline and contrast  
Steps in trans septal puncture are 
 
1. Accessing the left innominate vein with a multipurpose catheter  
2. An exchange length wire is introduced into the left innominate vein  
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3. Mullein sheath is introduced into the left innominate vein  
4. Removing the exchange wire from mullein sheath  
5. Introducing Brockenbrough needle  
 
6. Placing the pigtail catheter in aortic sinus  
7. Descending into the fossa ovalis region  
8. Confirming needle position in RAO view  
9. Confirming needle position in lateral view  
                                       
10. Aortic root contrast injection  
11. Septal puncture  
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COMPLICATIONS OF MITRAL VALVOTOMY  
1. Device related complications like breakage of coiled left atrial 
wire, entrapment of pigtail guide wire , balloon rupture during 
PTMC, balloon impasse  
2. Complications of transeptal puncture like suspected pericardial 
tamponade, hemopericardium 
3. Neurological complications like systemic embolism  
4. New onset arrhythmias- atrial fibrillation or flutter  
5. Complications needing emergency surgery are hemopericardium 
and cardiac tamponade, acute mitral regurgitation, LV perforation 
 
DEVICE RELATED COMPLICATIONS DURING PMV: 
BREAKAGE OF COILED LA WIRE: 
 Left atrial wire has two parts, the distal thin (coiled portion) and 
the proximal thick portion and both these parts are welded toghther. 
When the wire is used multiple times there is a greater tendency for 
breakage and this usually occurs at junction of proximal and distal 
portion junction from microfractures. The breaked wire may sometime 
get detached and embolised during manipulation. 
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The above picture shows the broken wire caught by snare going to 
be pulled back by the large sheath. This complication can be prevented by 
use of another left atrial wire made of NITINOL but there are no reports 
confirming this. Since the wire loop was too big, snares routinely used to 
catch the broken wire tip was not successful. 
 
ENTRAPMENT OF THE PIGTAIL CATHETER: 
 It’s a very rare complication; by the tip of guide wire got entrapped 
between the inner balloon lumen and the ballon stretching tube. While 
preparing ballon prior to percutaneous mitral valvotomy, it is important to 
note the following: 
1. Should not exceed maximum inflation volume on the syringe 
provided with balloon catheter. 
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2. Dilute contrast medium should be injected slowly to inflate the 
balloon during test inflations to avoid mesh layer over 
stretching. 
BALOON RUPTURE 
 It is  a rare complication. Occurs commonly in developing world, 
where balloon catheters are re-used. The two problems resulting from 
rupture of balloon were: 
1. Latex material or the wire mesh can be declared and get 
embolize to the arterial system but very rare possibility. 
2. While preparing contrast get mixed with air may embolize and 
produce air embolism in various organs: 
Balloon rupture during percutaneous mitral valvotomy 
1. Just before rupture: 
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2. Just after rupture: 
               
BALOON IMPASSE: 
 When INOUE catheter is used in percutaneous mitral valvotomy, 
sometimes even when properly aligned and defolded got held up or 
checked at the mitral valve referred to as the “balloon impasse” and it 
reflects severe obstructive subvalvular disease. This sign indicates severe 
mitral regurtitation when ballon used is of usual size. This can be averted 
by switching over to smaller ballons. 
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MITRAL VALVOTOMY IN SPECIAL SITUATIONS 
PERCUTANEOUS MITRAL VALVOTOMY IN PREGNANCY 
MITRAL STENOSIS AND PREGNANCY 
 Rheumatic heart remains the most common type of heart disease in 
pregnant woman in developing countries, and upto 75% of these will 
have mitral stenosis. The normal mitral valve has no pressure gradient 
across, and the increased cardiac output is well tolerated. However in 
mitral stenosis a gradient exists across the left atrium and left ventricle, 
the magnitude of which depends upon the severity of the stenosis and 
blood flow. When the cardiac output increases in pregnancy, mitral valve 
flow increases resulting in an increased gradient across the valve. So the 
following increase in left atrial pressure causes the pulmonary venous 
hypertension and an increased risk of pulmonary edema. The pulmonary 
arterial and right ventricular pressure is elevated and this eventually 
results in right ventricular pressure. The significance of mitral stenosis in 
pregnancy is that it not only leads to low systemic perfusion, but also to 
pulmonary congestion in about 25 % of the patients. 
 During labour due to large shift of fluid from the placenta to the 
maternal circulation results in tachycardia and is accompanied by 
disproportionate reduction of diastolic filling period across the mitral 
valve and results in elevated left atrial pressures with consequent 
increased risk of pulmonary edema. Atrial irritability is increased in 
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pregnancy and can lead to catastrophe pulmonary edema during late 
pregnancy as well as thrombus formation and additional risk of 
cerebrovascular embolization. Hence because of these factors mitral 
stenosis in pregnancy if not appropriately treated results in high maternal 
mortality and morbidity. Ideally it is imperative to do percutaneous mitral 
valvotomy or surgical intervention before the patient conceives if severe 
symptomatic mitral stenosis is diagnosed in nonpregnant women and who 
wishes to conceive. 
 Medical therapy during pregnancy has been implemented as the 
first line of therapy but it has its own limitations. Diuretics when used 
will reduce the placental perfusion. Beta blockers can be used effectively 
to reduce the exertional tachycardia at the cost of fetal growth retardation, 
bradycardia or hypoglycaemia in newborn infant. The tachycardias of 
sinus origin and is poorly reponse to digoxin due to the fact that increased 
sympathetic tone in pregnancy overrides the effect of digoxin. 
 
INTERVENTIONS OF MITRAL STENOSISI IN PREGNANCY: 
            Relief of mitral valve obstruction is needed when symptoms 
persist but surgical mitral valvotomy, closed mitral valvotomy or open 
mitral valvotomy has a significant risk of fetal death. Surgical experience 
with closed commissurotomy has declined over the past few years and 
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this is largely replaced by open commissurotomy or percutaneous 
techniques in most centers. 
 
PERCUTANEOUS MITRAL VALVOTOMY IN PREGNANCY 
 It’s an good alternative in patients of mitral stenosis in pregnancy. 
The most valuable method is the INOUE TECHNIQUE as the 
fluoroscopy time is short in this method. Some of the disadvantages of 
this method in pregnancy is that radiation hazards, complications like 
mitral regurgitation, hypotension, pericardial tamponade and fetal distress 
due to various above said reasons. The procedure should not be 
proceeded during organogenesis due to the various radiation hazard 
complications. Left ventriculography and right heart catheterization are 
avoided to reduce fluoroscopy time. The average estimated radiation dose 
received by the fetus during the procedure is 0.2 rad. There will be some 
technical problems during pregnancy like hypercoagulable state 
necessitates a quick transseptal puncture and after that heparin needs to 
be administered. Percutaneous mitral valvotomy can be performed 
starting from the 12th week of gestation. 
PERCUTANEOUS MITRAL VALVOTOMY IN JUVENILE 
MITRAL STENOSIS: 
 Many studies have suggested that percutaneous mitral valvotomy 
have been a very successful procedure in cases of juvenile rheumatic 
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mitral stenosis which usually includes age group less than 20 years. Even 
below the age group of 12 years the procedure has shown successful 
results and is safe and effective. 
 Because of the high transmitral gradients and high pulmonary 
artery pressures in juvenile mitral stenosis, they are candidates for early 
therapeutic intervention. Juvenile Mitral valve morphology differs from 
that of adults by having minimal calcification, lesser subvalvular 
pathology and lower mitral valve score. It is better to do the procedure 
under general anesthesia with sedation, and using a 4F or 5F sheath to 
avoid arterial access problems. In practice good results have been 
obtained while using double balloon technique, Inoue technique cribier’s 
metallic commisurotomy. 
 As in adults juvenile patients will have significant improvement in 
hemodynamic parameters after percutaneous mitral valvotomy. Juvenile 
patients will have lesser incidence of residual stenosis, but with no 
significant difference in invasively determined mean left atrial pressure, 
systolic pulmonary arterial pressure or pulmonary vascular resistance. 
 The complication rate is actually less when compared to adults. 
The reasons for low complication in juvenile patients are that attributed to 
more favorable valve anatomy, and also there is low incidence of embolic 
manifestations. On long term follow up there is no significant difference 
in pulmonary artery pressure between juvenile and adults. 
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 It is hypothesized that the children’s and adolescents patients may 
be more prone to restenosis because of the increased likelihood of 
smoldering rheumatic activity or recurrence of rheumatic fever in this 
age. But midterm and long term studies have proved that there is lower 
incidence of restenosis and also most restenosis patients will have pliable 
mitral valve apparatus suitable for a reprocedure. 
PERCUTANEOUS MITRAL VALVOTOMY IN MITRAL 
RESTENOSIS: 
 Hemodynamic studies states that restenosis can ocuur in those 
cases when the mitral valvotomy widened the orifice only slightly or 
when the stenosis was near totally removed. There are two types of 
stenosis  
1. TRUE RESTENOSIS refers to that occurs after one or both 
commisures have been fully split. 
2. FALSE RESTENOSIS is actually not a restenosis and is due to 
inadequate original procedure and neither commissure was fully 
split. 
Post mitral valvotomy restenosis is defined as valve area of <1.5cm2 or a 
>50% loss of initial gain in valve area. Restenosis incidence has been 
reported to be range from 4 to 39%. The pathology of restenosis is not 
due to recurrence of fusion in the commisures but rather due to end stage 
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valvular disease such as severe fibrosis and calcification. The wilkins 
ECHO score representing the degree of both leaflet and subvalvular 
disease, deteriorated progressively indicating the progressive nature of 
the disease. 
There are two mechanisms by which the mitral apparatus gets 
restenosed: 1. A more common slow process due to turbulent flow-
trauma on the mitral valve and a 
2.Rapid process that relates to vasculitis due to subclinical 
occurrence of low rheumatic activity. 
                The treatment options for these patients are mitral valve 
replacement or a repeat closed mitral valvotomy or a percutaneous mitral 
valvotomy. The treatment of choice in young patients with favorable 
wilkins score is repeat percutaneous mitral valvotomy, especially those 
with minimal lesions in subvalvular apparatus in whom the mechanism of 
restenosis is mainly bilateral commissural fusion. In patients with high 
wilkins score >7 repeat percutaneous mitral valvotomy may be 
considered as palliative procedure.  
 The success rate for percutaneous mitral valvotomy is 80-95% in 
denovo mitral stenosis, whereas it is about 50-90% in the case of 
restenosis. The percutaneous mitral valvotomy with mitral valve 
restenosis after a prior percutaneous valvuloplasty has a lesser event rates 
45 
 
compared to patients with restenosis after prior surgical 
commissurotomy. 
 The major issues technically dealt while doing percutaneous mitral 
valvotomy as follows: 
1. Septal puncture 
2. Multiple slow dilations may be needed to dilate the subvalvular 
region  and this may increase the risk of mitral regurgitation 
3. Restenosis patients are usually older and with associated 
comorbidities. 
 
COMPARISON OF PTMC AND SURGICAL VALVOTOMY  
 
 
            After its introduction in 1984 by Inoue in 1984, percutaneous 
mitral valvotomy has
management of selected patients with mitral stenosis, which is severe 
and symptomatic. 
PTMC over surgical commissurotomy
still remains the 
thrombus or disease of other valves like significant aortic disease. 
           Studies comparing percutaneous mitral valvotomy 
commissurotomy shows similar outcomes following both, with resp
to immediate hemodynamic outcomes 
proved this in their study.
mitral regurgitat
showed that patients undergoing mitral valvotomy 
outcomes in mitral valve orifice area. 
          
46 
 become the treatment of choice in the 
Many studies have established the superiority of 
. But surgical commissurotomy 
treatment of choice in patients with left atrial 
and MVOA. 
 The procedure related complications like 
ion were similar between two procedures. Patel et al 
 
 
with surgical 
ect 
Turi et al have 
had better 
   Studies which did late follow up of the two procedures 
Farhan et al showed better outcomes of the PTMC and OMC 
procedures when compared to 
valve area increased much more with PTMC and OMC than CMC . 
There was a less successful splitting of commis
commissurotomy when compared to open 
PTMC. Residual mitral stenosis was about 
OMC  when com
mitral valve area by echocardiography were equally higher in the 
PTMC and OMC groups 
rate was 6.6% after PTMC or OMC 
from re intervention
after CMC. The mean preprocedural 
different between the groups of PTMC, OMC and
              Another study comparing
reported better functional
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closed mitral commissurotomy. 
sures on closed mitral 
mitral valvotomy and 
zero percent in PTMC and 
pared to 27 % in CMC .at seven years follow up 
when compared to CMC group. Re stenosis 
versus 37 % of CMC. Freedom 
 was 90% after PTMC, 93% after OMC and 50% 
echocardiography score were not 
 CMC
 7 year results of PTMC and OMC 
 recovery, better mitral valve 
like Ben 
Mitral 
the 
.  
area and lesser 
 mitral regurgitation after OMC
study for nine months by rifaie et al comparing PTMC and CMC 
patients with pliable mitral valves reported 
term results in both the groups . Mitral restenosis occurred in 26% 
PTMC group and 27.8% in CMC group. None of the patients in either 
group developed significant mitral regurgitation 
              Song et al 
PTMC and surgical treatment. Patients with higher echocardiography 
scores and atrial fibrillation had better results with surgery. 
 
PTMC VERSUS SURGICAL COMMISSUROTOMY IN 
PREGNANCY 
              Of the available studies cumulatively 
pregnant patients
48 
. A long term follow up of randomised 
similar immediate 
 
have sought to compare the long term results of 
involving around 515 
 women who underwent PTMC, procedural success 
in 
and long 
of 
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was attained in about 98% patients, with one maternal death and ten 
fetal abnormalities. In an observational study comparing PTMC and 
open mitral commissurotomy the fetal outcomes were better with 
PTMC with fetal mortality rates of 6% in PTMC group versus 33 % in 
OMC group with similar procedural success between the two groups.  
             Pavan Kumar et al in their study of 126 pregnant patients who 
underwent CMC reported full term normal deliveries in 82 % and fetal 
loss in 6%.  
 
PTMC VERSUS SURGICAL COMMISSUROTOMY IN 
CALCIFIC MITRAL VALVE  
                  Heavily calcified mitral valve with bicommissural 
calcification is best dealt with valve replacement. OMC has the advantage 
in view of the feasibility of debridement of the valve calcification. There 
is no direct comparison of PTMC of PTMC and surgical 
commissurotomy in patients with lesser degree of calcification. Leaflet 
calcification was found to be a predictor of late mortality in a study by 
hickey et al . Another study by deter et al reported the association of 
higher late mortality as well as late re operation risk with leaflet 
calcification. 
                    Some studies have assessed the effect of fluoroscopic valve 
calcification on PTMC.  As expected these subset of patients with 
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significantly calcified valves on fluroscopy had poorer procedural 
outcome and in hospital mortality. The estimated two year survival was 
significantly lower for patients with heavily calcified mitral valve than 
those with non calcified valve. Freedom from mitral valve replacement at 
two years was also significantly lower for patients with calcified valves. 
In the study by lung et al for those patients who had a good immediate 
outcome, survival without reintervention at eight years was 48 percent 
only where as it was 40 percent for those who had poor hemodynamic 
outcome  
The effect of commissural calcification was analysed in an 
observational study by Sutaria et al. The authors classified commissural 
calcium from a grade of 0-3. They found that the PTMC results were 
better among patients with echocardiography score of less than eight and 
either grade zero or grade one calcification. Significant mitral 
regurgitation occurred in 4.1 percent of patients with grade 2 or grade 
3calcification.  
 
PTMC VERSUS SURCAL COMMISSUROTOMY IN PATIENTS 
WITH MITRAL RESTENOSIS: 
                There are no direct head to head comparisons of PTMC and 
surgical commissurotomy for mitral restenosis. The study by Nair et al 
reported procedural success of 59% for PTMC in mitral restenosis as 
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against 80-95 percent in native valves. Procedural successes varying from 
59-90% have been reported for PTMC in restenosed valves. There was no 
difference in outcome between the post PTMC restenosis versus post 
surgical restenosis groups. The reported rates of severe mitral 
regurgitation after PTMC in the group of patients range from 2.5 to 10 
percent. Repeat surgical commissurotomy has an operative risk mortality 
of 2.5 to 10%. High risk of systemic embolism upto four percent was 
seen. Operative success and functional class improvement were 50-85 
percent.  
 
 
 
 
 
 
 
 
 
 
 
    
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS: 
In this following hospital based observational study titled “AN 
OBSERVATIONAL STUDY TO ASSES IMMEDIATE 
HEMODYNAMIC OUTCOMES IN PATIENTS  UNDERGOING 
PERCUTANEOUS TRANSVENOUS MITRAL COMMISUROTOMY 
IN OUR INSTITUTION ”, fifty patients who were admitted as inpatients 
for the above procedure in the department of cardiology where followed 
up during intraoperative and postoperative period. 
 Period of study: April 2016 to September 2016 
 Study design: Observational study 
 Study centre: Department of cardiology,MMC, RGGGH. 
 Sample size: 50 
          Conflict of interest : none 
INCLUSION CRITERIA: 
Patients with rheumatic mitral stenosis: 
1. Symptomatic patients in NYHA Class II-IV 
2. Moderate to severe mitral stenosis as assessed by 
Echocardiography (MVOA</= 1.5cm2) 
3. Suitable mitral valve morphology with Wilkins score less than or 
equal to 8 
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EXCLUSION CRITERIA: 
1. Asymptomatic patients. 
2. Presences of left atrial thrombus in transesophageal ECHO. 
3. More than moderate MR 
4. Severe TR 
5. Severe concomitant aortic valve disease 
 
DATA COLLECTION AND METHODS: 
 Data collection was performed by preoperative and intraoperative 
follow up. Patients who had a Wilkins score of less than 8 who were 
posted for PTMC where considered in the study. Immediate functional 
outcome of the procedure in terms of hemodynamic improvement was 
assessed by measuring the percentage of improvement in mitral valve 
orifice area, Left atrial pressure and mitral valve peak gradient. 
Intraoperative complications if any were noted. 
 
PROCEDURE / INVESTIGATION DETAILS: 
PATIENT SELECTION: 
 
A) Clinical criteria used for symptom assessment –NYHA classification 
B) Severity assessment- 1.MVOA assessed by 2D transthoracic ECHO 
planimetry 
C) Valve morphology assessment- Wilkins ECHO score by 2D TTE 
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D) Assessment for left atrial clot- Transesophageal ECHO 
E) Atrial fibrillation-12 lead standard ECG  
HEMODYNAMICS ASSESSMENT: 
1. MVOA-2D ECHO planimetry           
 2. Mitral peak flow gradient- 2 D Doppler ECHO                                        
3. MR/TR-2D TTE  
4. LA pressure assessed by intraoperative cardiac catheter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATIONS AND RESULTS  
55 
 
RESULTS 
AGE DISTRIBUTION 
 
                Out of the 50 patients of our study group, 64% of patients 
lie in the 21-40 age, only 2% of the patients lie in the 61-80 age 
group.        
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Valid 
0-20 6 12.0 12.0 12.0 
21-40 32 64.0 64.0 76.0 
41-60 11 22.0 22.0 98.0 
61-80 1 2.0 2.0 100.0 
Total 50 100.0 100.0  
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78%
Out of the 50 patients of our study group 78 % were female and 22% were male
 
 Frequency
Valid 
MALE 
FEMALE 
Total 
56 
 
22%
GENDER
SEX DISTRIBUTION 
 
 Percent Valid Percent
11 22.0 22.0 
39 78.0 78.0 
50 100.0 100.0 
 
MALE
FEMALE
 
 Cumulative 
Percent 
22.0 
100.0 
 
  
 
 
 
48%
 
Out of the 50 patients in our study group 52 % had symptoms in class II
 
 NYHA and 41% had symptoms in class  III NYHA and 0% in class I 
and IV  
 
NYHA 
 Frequency
NYHA 
2.00 
3.00 
Total 
57 
 
 
52%
NYHA
NYHA CLASS 
 Percent Valid Percent 
26 52.0 52.0 
24 48.0 48.0 
50 100.0 100.0 
 
2
3
 
Cumulative 
Percent 
52.0 
100.0 
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WILKINS SCORE 
 
Out of the 50 patients in our study group, all 100 % had a Wilkins score of 
less than or equal to 8. 30% patients had a score of 6 which was the 
maximum, 8% patients had a score of 4 which was the minimum  
 Frequency Percent Valid Percent Cumulative 
Percent 
Wilkin
s score 
4.00 4 8.0 8.0 8.0 
5.00 12 24.0 24.0 32.0 
6.00 15 30.0 30.0 62.0 
7.00 7 14.0 14.0 76.0 
8.00 12 24.0 24.0 100.0 
Total 50 100.0 100.0  
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INCIDENCE OF ATRIAL FIBRILLATION
Out of 50 patients in our study group, 16% had atrial 
 
fibrillation and 84 % had no atrial fibrillation 
 
 Frequency
A.fib 
No 
Yes 
Total 
59 
 
84%
16%
A FIB
 
 
 
 Percent Valid Percent
42 84.0 84.0 
8 16.0 16.0 
50 100.0 100.0 
 
NO
YES
 
 Cumulative 
Percent 
84.0 
100.0 
 
  
 
 
 
 
 
 
58%
OPTIMAL RESULT WITH REGARD TO MITRAL VALVE ORIFICE 
AREA, LA PRESSURE AND MITRAL VALVE PEAK GRADIENT
 
Optimal result is defined as doubling of MVOA, that is a
 
 increase in mitral valve orifice area, a fifty percent reduction in LA pressure and 
 
50 percent reduction in MVPG
  
 
result 
abnormal
normal (optimal 
result) 
Total 
60 
42%
OPTIMAL RESULT
 fifty
 
Frequency Percent Valid 
Percent
 21 42.0 42.0
29 58.0 58.0
50 100.0 100.0
 
ABNORMAL 
NORMAL 
 
 percent 
 
 
Cumulative 
Percent 
 42.0 
 100.0 
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OPTIMAL RESULT IN AGE GROUPS 
 
 
Age group of 0 – 20 yrs  had the maximum overall optimal result of the 
procedure 
 
 
 
 
 
 
 
optimal result Total 
abnormal normal 
(optimal 
result) 
Age group 
0-20 
Count 0 6 6 
% within optimal 
result 0.0% 20.7% 12.0% 
21-40 
Count 11 21 32 
% within optimal 
result 52.4% 72.4% 64.0% 
41-60 
Count 9 2 11 
% within optimal 
result 42.9% 6.9% 22.0% 
61-80 
Count 1 0 1 
% within optimal 
result 4.8% 0.0% 2.0% 
Total 
Count 21 29 50 
% within optimal 
result 100.0% 100.0% 100.0% 
 
 
Pearson Chi-Square= 13.649* P=0.003 
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OPTIMAL MVOA IN AGE GROUP 
 
Age group  0 – 20  had the maximum improvement with regard to MVOA 
 
 MVOA group Total 
Abnormal 
(<50%) 
Normal 
(>50%) 
age group 
0-20 
Count 2 4 6 
% within MVOA 
group 8.0% 16.0% 12.0% 
21-40 
Count 13 19 32 
% within MVOA 
group 52.0% 76.0% 64.0% 
41-60 
Count 9 2 11 
% within MVOA 
group 36.0% 8.0% 22.0% 
61-80 
Count 1 0 1 
% within MVOA 
group 4.0% 0.0% 2.0% 
Total 
Count 25 25 50 
% within MVOA 
group 100.0% 100.0% 100.0% 
Pearson Chi-Square= 8.016* P=0.046 
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OPTIMAL RESULT IN AGE GROUP WITH REGARD TO 
IMPROVEMENT IN LA PRESSURE 
 
 
Pearson Chi-Square= 11.469* P=0.009 
 
 
 
Age group of 0-20 had the maximum optimal result with regard to LA pressure 
but the association was not statistically significant 
 
 
 LA PRESSURE group Total 
Abnormal 
(50%) 
Normal 
(>50%) 
age_grou
p 
0-20 
Count 1 5 6 
% within LA 
PRESSURE group 3.8% 20.8% 12.0% 
21-40 
Count 14 18 32 
% within LA 
PRESSURE__group 53.8% 75.0% 64.0% 
41-60 
Count 10 1 11 
% within 
LA_PRESSURE__gr
oup 
38.5% 4.2% 22.0% 
61-80 
Count 1 0 1 
% within 
LA_PRESSURE__gr
oup 
3.8% 0.0% 2.0% 
Total 
Count 26 24 50 
% within 
LA_PRESSURE__gr
oup 
100.0% 100.0% 100.0% 
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OPTIMAL RESULT IN MVPG WITH REGARD TO AGE GROUP 
Age group of 0-20 yrs has the maximum optimal result with regard to  
MVPG 
 
 MVPG_group Total 
Abnormal 
(<50%) 
Normal 
(>50%) 
age_group 
0-20 
Count 0 6 6 
% within 
MVPG_group 0.0% 20.7% 12.0% 
21-40 
Count 11 21 32 
% within 
MVPG_group 52.4% 72.4% 64.0% 
41-60 
Count 9 2 11 
% within 
MVPG_group 42.9% 6.9% 22.0% 
61-80 
Count 1 0 1 
% within 
MVPG_group 4.8% 0.0% 2.0% 
Total 
Count 21 29 50 
% within 
MVPG_group 100.0% 100.0% 100.0% 
     
Pearson Chi-Square= 13.649* P=0.003 
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OVERALL OPTIMAL RESULT IN SEX GROUPS 
 
No significant association with sex groups and  overall better outcomes with 
regard to optimal results 
 
 optimal_result Total 
abnormal normal 
(optimal 
result) 
SEX 
MALE 
Count 8 3 11 
% within 
optimal_result 38.1% 10.3% 22.0% 
FEMAL
E 
Count 13 26 39 
% within 
optimal_result 61.9% 89.7% 78.0% 
Total 
Count 21 29 50 
% within 
optimal_result 100.0% 100.0% 100.0% 
Pearson Chi-Square= 5.466 * P=0.019 
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OPTIMAL RESULT WITH REGARD TO MVOA IN SEX GROUPS 
No significant association with sex group and overall better outcome with 
regard to MVOA 
 
 MVOA_group Total 
Abnormal 
(<50%) 
Normal 
(>50%) 
SEX 
MALE 
Count 8 3 11 
% within 
MVOA_group 32.0% 12.0% 22.0% 
FEMAL
E 
Count 17 22 39 
% within 
MVOA_group 68.0% 88.0% 78.0% 
Total 
Count 25 25 50 
% within 
MVOA_group 100.0% 100.0% 100.0% 
 
Pearson Chi-Square= 2.914 
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OPTIMAL RESULT WITH REGARD TO LA PRESSURE IN SEX 
GROUPS 
 
No significant association was found 
 
 LA_PRESSURE__group Total 
Abnormal 
(<50%) 
Normal 
(>50%) 
SEX 
MALE 
Count 8 3 11 
% within 
LA_PRESSURE__gro
up 
30.8% 12.5% 22.0% 
FEMAL
E 
Count 18 21 39 
% within 
LA_PRESSURE__gro
up 
69.2% 87.5% 78.0% 
Total 
Count 26 24 50 
% within 
LA_PRESSURE__gro
up 
100.0% 100.0% 100.0% 
Pearson Chi-Square= 2.427 * P=0.119 
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Pearson Chi-Square= 5.466 * P=0.019 
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OPTIMAL RESULT WITH REGARD TO MVPG IN SEX GROUPS 
 MVPG_group Total 
abnormal 
(<50%) 
normal 
(>50%) 
SEX 
MALE 
Count 8 3 11 
% within 
MVPG_group 38.1% 10.3% 22.0% 
FEMAL
E 
Count 13 26 39 
% within 
MVPG_group 61.9% 89.7% 78.0% 
Total 
Count 21 29 50 
% within 
MVPG_group 100.0% 100.0% 100.0% 
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OVERALL OPTIMAL RESULTS WITH REGARD TO NYHA 
CLASS 
 
 optimal_result Total 
abnorma
l 
normal 
(optimal 
result) 
NYHA 
CLASS 
2.00 
Count 6 17 23 
% within 
optimal_result 28.6% 58.6% 46.0% 
3.00 
Count 15 12 27 
% within 
optimal_result 71.4% 41.4% 54.0% 
Total 
Count 21 29 50 
% within 
optimal_result 100.0% 100.0% 100.0% 
Pearson Chi-Square= 4.428 * P=0.035 
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OPTIMAL RESULT IN MVOA WITH REGARD TO NYHA 
CLASS 
 
 MVOA_group Total 
Abnormal 
(<50%) 
Normal 
(>50%) 
NYHA 
CLASS 
2.00 
Count 9 14 23 
% within 
MVOA_group 36.0% 56.0% 46.0% 
3.00 
Count 16 11 27 
% within 
MVOA_group 64.0% 44.0% 54.0% 
Total 
Count 25 25 50 
% within 
MVOA_group 100.0% 100.0% 
100.0
% 
Pearson Chi-Square= 2.013 * P=0.156 
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Pearson Chi-Square= 1.239  P=0.266 
 
  
OPTIMAL RESULTS IN LA PRESSURE WITH REGARD TO NYHA 
CLASS 
 
 LA_PRESSURE__group Total 
Abnormal 
(<50%) 
Normal 
(>50%) 
NYHA_CL
ASS 
2.00 
Count 10 13 23 
% within 
LA_PRESSURE__gr
oup 
38.5% 54.2% 46.0% 
3.00 
Count 16 11 27 
% within 
LA_PRESSURE__gr
oup 
61.5% 45.8% 54.0% 
Total 
Count 26 24 50 
% within 
LA_PRESSURE__gr
oup 
100.0% 100.0% 100.0% 
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Pearson Chi-Square= 4.428 * P=0.035 
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OPTIMAL RESULT WITH REGARD TO MVPG AND NYHA CLASS 
 MVPG_group Total 
Abnormal 
(<50%) 
Normal 
(>50%) 
NYHA_CLA
SS 
2.00 
Count 6 17 23 
% within 
MVPG_group 28.6% 58.6% 46.0% 
3.00 
Count 15 12 27 
% within 
MVPG_group 71.4% 41.4% 54.0% 
Total 
Count 21 29 50 
% within 
MVPG_group 100.0% 100.0% 100.0% 
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optimal_result Total 
abnorm
al 
normal 
(optimal 
result) 
WILKINS_S
CORE 
4.00 
Count 0 4 4 
% within 
optimal_result 0.0% 13.8% 8.0% 
5.00 
Count 3 9 12 
% within 
optimal_result 14.3% 31.0% 24.0% 
6.00 
Count 4 11 15 
% within 
optimal_result 19.0% 37.9% 30.0% 
7.00 
Count 5 2 7 
% within 
optimal_result 23.8% 6.9% 14.0% 
8.00 
Count 9 3 12 
% within 
optimal_result 42.9% 10.3% 24.0% 
Total 
Count 21 29 50 
% within 
optimal_result 100.0% 100.0% 100.0% 
Pearson Chi-Square= 13.621 * P=0.009 
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Pearson Chi-Square= 20.505* P<0.001 
 
OPTIMAL RESULT IN INCREASE IN MVOA WITH REGARD TO 
WILKINS SCORE 
 
The association between Wilkins score and outcome of PTMC with regard  
 
to optimal result in mitral valve orifice area was statistically significant  
 
with patients having a lower Wilkins score having a better outcome of the  
 
surgery. Optimal result of PTMC with regard to MVOA is an increase in  
 
MVOA of 50 % of the baseline valve area. 
 
 MVOA_group Total 
abnormal 
(<50%) 
normal 
(>50%) 
WILKINS_SC
ORE 
4.00 
Count 0 4 4 
% within 
MVOA_group 0.0% 16.0% 8.0% 
5.00 
Count 4 8 12 
% within 
MVOA_group 16.0% 32.0% 24.0% 
6.00 
Count 4 11 15 
% within 
MVOA_group 16.0% 44.0% 30.0% 
7.00 
Count 6 1 7 
% within 
MVOA_group 24.0% 4.0% 14.0% 
8.00 
Count 11 1 12 
% within 
MVOA_group 44.0% 4.0% 24.0% 
Total 
Count 25 25 50 
% within 
MVOA_group 100.0% 100.0% 100.0% 
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OPTIMAL RESULTS OF PTMC WITH REGARD TO REDUCTION IN 
LA PRESSURE AND WILKINS SCORE 
 
The association between the optimal reduction in LA pressure post PTMC  
 
and Wilkins score was found to be statistically significant . The results were  
 
optimal with lower Wilkins scores. The optimal reduction is LA pressure is  
 
50% from the base line 
 
 LA_PRESSURE__gr
oup 
Total 
abnormal 
(<50%) 
normal 
(>50%) 
WILKINS_SC
ORE 
4.00 
Count 0 4 4 
% within 
LA_PRESSURE__gr
oup 
0.0% 16.7% 8.0% 
5.00 
Count 4 8 12 
% within 
LA_PRESSURE__gr
oup 
15.4% 33.3% 24.0% 
6.00 
Count 5 10 15 
% within 
LA_PRESSURE__gr
oup 
19.2% 41.7% 30.0% 
7.00 
Count 6 1 7 
% within 
LA_PRESSURE__gr
oup 
23.1% 4.2% 14.0% 
8.00 
Count 11 1 12 
% within 
LA_PRESSURE__gr
oup 
42.3% 4.2% 24.0% 
Total 
Count 26 24 50 
% within 
LA_PRESSURE__gr
oup 
100.0% 100.0% 100.0% 
Pearson Chi-Square= 18.855*  P=0.001 
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Pearson Chi-Square= 13.621*p<0.001  
OPTIMAL RESULT WITH REGARD TO MVPG AND WILKINS SCORE 
 
The association was found to be statistically significant and patients with 
 
Lower Wilkins score had a better outcome in terms of MVPG. Optimal    
 
MVPG is a decrease of 50% from the baseline 
 
 
 MVPG_group Total 
abnormal 
(<50%) 
normal 
(>50%) 
WILKINS_SC
ORE 
4.00 
Count 0 4 4 
% within 
MVPG_group 0.0% 13.8% 8.0% 
5.00 
Count 3 9 12 
% within 
MVPG_group 14.3% 31.0% 24.0% 
6.00 
Count 4 11 15 
% within 
MVPG_group 19.0% 37.9% 30.0% 
7.00 
Count 5 2 7 
% within 
MVPG_group 23.8% 6.9% 14.0% 
8.00 
Count 9 3 12 
% within 
MVPG_group 42.9% 10.3% 24.0% 
Total 
Count 21 29 50 
% within 
MVPG_group 100.0% 100.0% 100.0% 
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Pearson Chi-Square= 1.643  p=0.200 
 
ATRIAL FIBRILLATION AND  MITRAL VALVE ORIFICE AREA 
 MVOA_group Total 
abnormal 
(<50%) 
normal 
(>50%) 
ATRIAL 
FIBRILL
ATION 
N 
Count 19 23 42 
% within 
MVOA_group 76.0% 92.0% 84.0% 
Y 
Count 6 2 8 
% within 
MVOA_group 24.0% 8.0% 16.0% 
Total 
Count 25 25 50 
% within 
MVOA_group 100.0% 100.0% 100.0% 
Pearson Chi-Square= 2.381  P=0.123 
  
ATRIAL FIBRILLATION  AND OUTCOME OF PTMC 
 
 optimal_result Total 
abnormal normal 
(optimal 
result) 
ATRIAL 
FIBRILL
ATION 
N 
Count 16 26 42 
% within 
optimal_result 76.2% 89.7% 84.0% 
Y 
Count 5 3 8 
% within 
optimal_result 23.8% 10.3% 16.0% 
Total 
Count 21 29 50 
% within 
optimal_result 100.0% 100.0% 100.0% 
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Pearson Chi-Square= 2.018  P=0.155 
Crosstab 
 MVPG_group Total 
Abnormal 
(<50%) 
Normal 
(>50%) 
A#FI
B 
N 
Count 16 26 42 
% within 
MVPG_group 76.2% 89.7% 84.0% 
Y 
Count 5 3 8 
% within 
MVPG_group 23.8% 10.3% 16.0% 
Total 
Count 21 29 50 
% within 
MVPG_group 100.0% 100.0% 100.0% 
 
Pearson Chi-Square= 1.643 P=0.200 
 
  
ATRIAL FIBRILLATION AND ITS EFFECT ON LA PRESSURE 
 LA_PRESSURE__group Total 
abnormal 
(<50%) 
normal 
(>50%) 
ATRIAL 
FIBRILLA
TION 
No 
Count 20 22 42 
% within 
LA_PRESSURE__gro
up 
76.9% 91.7% 84.0% 
Yes 
Count 6 2 8 
% within 
LA_PRESSURE__gro
up 
23.1% 8.3% 16.0% 
Total 
Count 26 24 50 
% within 
LA_PRESSURE__gro
up 
100.0% 100.0% 100.0% 
84 
 
RELATIONSHIP BETWEEN WILKINS SCORE AND THREE 
PARAMETERS FOR OUTCOME OF SURGERY 
 
 
 
 
** CORRELATION IS significant AT P<0.001 
 
  
 MVOA 
INCREASE 
LA 
PRESSURE
DECREASE 
MVPG 
DECREASE 
WILKINS_SCORE 
Pearson 
Correlation -.548
**
 -.569** -.566** 
P  VALUE .000 .000 .000 
N 50 50 50 
DISCUSSION 
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DISCUSSION 
 Out of the 50 patients who were included in the study group 64% 
were in 21-40 age group, 78% were females, 52% have symptoms and 
NYHA II, 48% have symptoms in NYHA class III, 0% in NYHA class I 
& IV. All the patients had wilkins score of 8 or below. Out of the 50 
patients 84% had no atrial fibrillation. 
 Optimal results of the procedure was taken as 50% increase in 
mitral valve orifice area, 50% decrease in left atrial pressure, 50% 
decrease in mitral valve peak gradient. The outcome of the procedure in 
terms of all the three parameters was studied.  
 Even though lower age group, female sex, no atrial fibrillation and 
lower NYHA class seemed to have better outcomes the association was 
not statistically significant. The association between wilkins score and 
outcome with regard to all three parameters was statistically significant. 
 
  
CONCLUSION 
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CONCLUSION 
           It was the findings of the study that patients with lower age, lower 
NYHA class, patient not in atrial fibrillation, female sex, lower ECHO 
cardiographic score were all found to have better hemodynamic 
outcomes. But patients with lower Wilkins score had a statiscally 
significant hemodynamic improvement. This shows that even though 
ECHO cardiographic scores are not the only parameters determining the 
outcome of PTMC, they still have a significant role in patient selection 
for PTMC. 
From all the discussions above, it is evident that PTMC is the 
procedure of choice for the management of uncomplicated and pliable 
mitral stenosis. Even in unfavourable situations PTMC has a place in the 
treatment of the disease especially in the developing world, where the 
facilities for mitral valve replacement are limited.  
Problems of anticoagulation are also common in these settings. So 
PTMC can overcome this problem. PTMC has an advantage over closed 
mitral commissurotomy and may be on par with open mitral 
commissurotomy for a pliable valve. 
It is a better option than surgical mitral commissurotomy in 
pregnant patients. In the presence of an LA thrombus, PTMC has no role 
and open mitral commissurotomy is the procedure of choice in this 
setting. 
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 ABBREVIATIONS 
PTMC  -  Percutaneous transvenous mitral commissurotomy 
MVOA  -  Mitral valve orifice area 
RHD   -  Rheumatic heart disease 
MS   -  Mitral stenosis 
MVMG  - Mitral valve mean gradient 
MVPG  -  Mitral valve peak gradient  
OMC  - Open mitral commisurotomy 
CMC   - Closed mitral commisurotomy 
            
 
 
 
 
 
 
 
ANNEXURES 
 
  
PRO-FORMA 
 
 
NAME:                                      AGE:                    SEX:                   CD 
No: 
ADDRESS:                                                                                         MRD 
No: 
                                                                                                             
ANGIO No: 
DIAGNOSIS- 
 
NYHA CLASS-                                                                                 
WEIGHT- 
PROCEDURE DONE-                                                                       
HEIGHT- 
DATE- 
 
WILKINS ECHO SCORE 
         PARAMETERS POINTS 
THICKENING  
MOBILITY  
SUBVALVULAR FUSION  
CALCIFICATION  
TOTAL SCORE  
                                           
TRANSESOPHAGEAL ECHO- 
TECHNIQUE USED- DOUBLE BALOON/ INOUE/ OTHERS 
HARDWARE USED- 
BALOON SIZE- 
IAS PUNCTURE- RAO/ LATERAL/AP 
ANTICOAGULANTS/ INR- 
HEPARIN-    
ATRIAL FIBRILLATION- PRE PROCEDURE/ DURING/ POST 
PROCEDURE 
POST CMC or POST BMV- YES/ NO          IF YES- 
PREGNANCY- YES/ NO 
         PARAMETER PRE BMV POST BMV 
MVOA 
(PLANIMETRY)   
MITRAL FLOW PEAK 
GRADIENT   
MITRAL 
REGURGITATION   
TRICUSPID 
REGURGITATION   
LA PRESSURE   
 
COMPLICATIONS IF ANY- TECHNICAL FAILURE/ SUBOPTIMAL 
RESULT/ SEVERE MR/TAMPONADE/CVA/ DEATH/ OTHERS 
 
 
 
TURNITIN PLAGIARISM SCREEN SHOT 
 
 
  
TURNITIN PLAGIARISM RECEIPT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PATIENT INFORMATION SHEET 
                                                                                                                                                                                                                                                          
          We are conducting a study on “AN OBSERVATIONAL STUDY TO 
ASSESS  IMMEDIATE HEMODYNAMIC OUTCOMES IN PATIENTS 
UNDERGOING PERCUTANEOUS TRANSVENOUS MITRAL 
COMMISUROTOMY IN OUR INSTITUTION”  among patients who meet 
the selection criteria for PTMC and undergoing PTMC at Rajiv Gandhi 
Government General Hospital, Chennai  
The purpose of this study is to assess the success rate of the procedure 
and patients hemodynamic and clinical outcomes in our institution. 
We are selecting certain cases and if you are found eligible, we would 
like to collect preoperative assessment data, intraoperative data, postoperative 
assessment data, which in any way do not affect your final report or 
management. 
 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid 
in the management or treatment. 
 
 
 
Signature of the Investigator  Signature left thumb impression  
      participant 
Date: 
Place: 
  
  
PATIENT CONSENT FORM 
Study Detail :  “AN OBSERVATIONAL STUDY TO ASSESS  
IMMEDIATE HEMODYNAMIC OUTCOMES 
IN PATIENTS UNDERGOING 
PERCUTANEOUS TRANSVENOUS MITRAL 
COMMISUROTOMY IN OUR INSTITUTION” 
Study Centre : Institute of cardiology, Rajiv Gandhi Government 
General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the 
above study. I have the opportunity to ask question and all my 
questions and doubts have been answered to my complete 
satisfaction. ❏ 
  
I understand that my participation in the study is voluntary and that I 
am free to withdraw at any time without giving reason, without 
my legal rights being affected. ❏ 
 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory 
authorities will not need my permission to look at my health 
records, both in respect of current study and any further research 
that may be conducted in relation to it, even if I withdraw from 
the study I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third 
parties or published, unless as required under the law. I agree not 
to restrict the use of any data or results that arise from this study. ❏ 
 
I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperate with 
the study team and to immediately inform the study staff if I ❏ 
suffer from any deterioration in my health or well-being or any 
unexpected or unusual symptoms. 
I hereby consent to participate in this study. ❏ 
 
I hereby give permission to undergo complete clinical 
examination,and necessary investigations. ❏ 
 
 
 
 
 
Signature of Investigator     Signature/thumb impression 
Study Investigator’s Name:   Patient’s Name and Address: 
Dr.A.ARTHI 
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